[1] Backhed F. Host-bacterial mutualism in the human intestine. Science,2005,307（5717）:1915-1920.
[2] Maynard CL. Reciprocal interactions of the intestinal microbiota and immune system. Nature,2012,489（7415）:231-241.
[3] Seo YS,Shah VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol,2012,18（4）:337.
[4] Chen Y. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology,2011,54（2）:562-572.
[5] Miyake Y. Role of gut microbiota in liver diseases. Hepatol Res,2013,43（2）:139-146.
[6] Bellot P,Frances R,Such J. Bacterial translocation in cirrhosis. Gastroenterol Hepatol,2008,31（8）:508-514.
[7] Guarner C,Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol,2005,17（1）:27-31.
[8] Kakiyama G. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol,2013,58（5）:949-955.
[9] Cariello R. Intestinal permeability in patients with chronic liver diseases:Its relationship with the aetiology and the entity of liver damage. Dig Liver Dis,2010,42（3）: 200-204.
[10] 吴仲文,徐凯进,李兰娟. 78 例肝硬化患者肠道细菌异位及其相关性研究.中华外科杂志, 2006,44: 1456-1459.
[11] 翁秋青. 肝硬化及腹泻患者肠道菌群的比较研究. 国际医药卫生导报,2011,17（6）:678-679.
[12] Morgan MY. The treatment of hepatic encephalopathy. Metab Brain Dis,2007,22（3-4）:389-405.
[13] Debbia EA. Effects of rifaximin on bacterial virulence mechanisms at supra-and sub-inhibitory concentrations. Chemotherapy,2008,20（2）:186-194.
[14] Loguercio G. Cyclictreatment of chronic hepatic encephalopathy with rifaximin:results of a doubleblind clinical study. Minerva Gastroenterol Dietol,2003,49:53-62.
[15] Bass NM. Rifaximin treatment in hepatic encephalopathy. New Engl J Med,2010,362:1071-1081.
[16] Guarner C. Spontaneous bacterial peritonitis. Semin Liver Dis, 1997,17（3）:203-217.
[17] Campillo B. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients:impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis,2002, 35（1）:1-10.
[18] Almeida J. Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol,2006,12（10）:1493-1502.
[19] Schrier RW. Peripheral arterial vasodilation hypothesis:a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology, 1988, 8（5）: 1151-1157.
[20] Castro A,Jimenez W. Impaired responsiveness to angiotensin II in experimental cirrhosis:role of nitric oxide. Hepatology, 1993,18:367-372.
[21] Wiest R,Rath HC. Gastrointestinal disorders of the critically ill: Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol,2003,17（3）:397-425.
[22] Rimola A.Diagnosis,treatment and prophylaxis of spontaneous bacterial peritonitis:a consensus document. International Ascites Club. J Hepatol,2000,32（1）:142-153.
[23] Fernandez J. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology,2006,131（4）:1049-1056. |
